Janus Henderson Group
NKTR icon

Janus Henderson Group’s Nektar Therapeutics NKTR Stock Holding History

Janus Henderson Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$771K Buy
10,729
+2,629
+32% +$150K ﹤0.01% 1804
2025
Q4 		$342K Buy
+8,100
New +$453K ﹤0.01% 2153
2023
Q2 		– Sell
-5,507
Closed -$57.8K – 2644
2023
Q1 		$57.8K Buy
5,507
+3,075
+126% +$93K ﹤0.01% 2654
2022
Q4 		$82.3K Sell
2,432
-2,431
-50% -$118K ﹤0.01% 2364
2022
Q3 		$234K Buy
4,863
+2,436
+100% +$145K ﹤0.01% 2327
2022
Q2 		$138K Sell
2,427
-3
-0.1% -$189 ﹤0.01% 2413
2022
Q1 		$196K Sell
2,430
-125
-5% -$18.5K ﹤0.01% 2448
2021
Q4 		$518K Buy
2,555
+764
+43% +$166K ﹤0.01% 1871
2021
Q3 		$482K Buy
+1,791
New +$431K ﹤0.01% 1634
2021
Q2 		– Sell
-3,922
Closed -$1.18M – 1648
2021
Q1 		$1.18M Buy
+3,922
New +$1.22M ﹤0.01% 1255
2020
Q4 		– Sell
-3,323
Closed -$827K – 1415
2020
Q3 		$827K Sell
3,323
-923
-22% -$290K ﹤0.01% 1163
2020
Q2 		$1.48M Sell
4,246
-288
-6% -$89.9K ﹤0.01% 1073
2020
Q1 		$1.21M Sell
4,534
-71,285
-94% -$22M ﹤0.01% 1076
2019
Q4 		$24.5M Sell
75,819
-21,391
-22% -$6.2M 0.01% 775
2019
Q3 		$26.6M Sell
97,210
-65,874
-40% -$24.2M 0.01% 760
2019
Q2 		$87M Sell
163,084
-1,107
-0.7% -$555K 0.05% 416
2019
Q1 		$82.8M Sell
164,191
-4,273
-3% -$2.53M 0.05% 445
2018
Q4 		$83.1M Sell
168,464
-133,936
-44% -$80.8M 0.05% 404
2018
Q3 		$277M Sell
302,400
-23,998
-7% -$20.5M 0.15% 176
2018
Q2 		$239M Sell
326,398
-25,789
-7% -$29.7M 0.14% 195
2018
Q1 		$561M Buy
352,187
+98,499
+39% +$127M 0.33% 67
2017
Q4 		$227M Buy
253,688
+31,736
+14% +$18.8M 0.14% 192
2017
Q3 		$79.9M Buy
221,952
+103,757
+88% +$32.5M 0.05% 403
2017
Q2 		$34.7M Buy
+118,195
New +$34.2M 0.02% 613

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group's NKTR Position: Q1 2026 in Review

Janus Henderson Group increased its Nektar Therapeutics (NKTR) stake by 32% in Q1 2026, buying an estimated $150K and bringing the position to 10,729 shares worth $771K. The position accounts for ﹤0.01% of the portfolio, ranked #1804.

Janus Henderson Group first reported a position in NKTR in Q2 2017 and has held it in 24 quarters since. The position peaked at $561M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Janus Henderson Group held 10,729 shares of Nektar Therapeutics worth $771K as of Q1 2026.
  • Janus Henderson Group bought 2,629 Nektar Therapeutics shares in Q1 2026, an estimated $150K.
  • Nektar Therapeutics made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #1804 holding.
  • Janus Henderson Group first reported a position in Nektar Therapeutics in Q2 2017 and has held it in 24 quarters since.
  • Janus Henderson Group's Nektar Therapeutics position peaked at $561M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.